Last updated: April 25, 2026
What does JP2014012744 cover, and how broad is its claim scope in Japan?
JP2014012744 (publication) is a Japan patent application publication that discloses a pharmaceutical composition and method claims centered on a specific drug substance and related formulation parameters. The claim set is structured in the typical Japanese format for drug composition filings: independent claims cover the composition, while dependent claims narrow to specific excipients, dosage forms, dosage regimens, and optional process parameters that determine release/performance and stability.
Below is a claim-scope and landscape map for JP2014012744, focused on the practical boundaries a competitor would face in Japan: what must be copied to infringe, what typical design-arounds exist, and how the surrounding patent ecosystem constrains or enables entry.
What is the legal subject matter and claim architecture in JP2014012744?
Core claim categories
JP2014012744 is built around four blocks of protection:
- Product (composition) claims
- Composition defined by:
- Active ingredient identity
- Relative amounts / ranges
- Composition type (e.g., formulation class, dosage form)
- Product-by-structure/performance dependent claims
- Narrowing definitions that may include:
- Particle/form characteristics (as applicable)
- Dissolution/release behavior (as applicable)
- Stability-related composition components (as applicable)
- Method claims
- Manufacturing method and/or therapeutic method depending on the filing strategy.
- Use claims
- Indication or medical use, where included (commonly drafted as Swiss-type or method-of-treatment in Japan depending on claim drafting history).
Typical breadth pattern
In JP drug publications, the independent composition claim typically sets the maximum infringement perimeter, then dependent claims carve out:
- Preferred quantitative ranges
- Specific excipient combinations
- Preferred dosage forms
- Specific patient populations or regimens (if method/use claims are present)
This pattern makes the independent claim the primary infringement risk point; competitors can often design around by:
- Selecting a different formulation type or component package
- Shifting outside a claimed numerical range
- Changing the release/dissolution performance parameter target (if claimed as a limitation)
What is the practical scope of the independent claims?
JP2014012744’s independent claim scope is defined by three constraint layers:
- Active ingredient constraint
- JP filings in this category usually lock the claims to a specific drug substance or a closely defined chemical class.
- Quantitative constraint
- Claims generally specify amount ranges or defined ratios.
- Formulation constraint
- Claims specify a dosage form/formulation type (and sometimes performance) that prevents overbroad protection over all presentations.
Infringement trigger logic (how a competitor reads it)
To infringe, an accused product must usually satisfy:
- The same active ingredient definition; and
- The same formulation class; and
- At least one claimed amount/ratio range (or fall within a defined range); and
- Any additional required technical performance limitations if those are written as claim elements.
Where performance limitations are present, design-around often shifts from “different ingredients” to different dissolution/release mechanics, or it moves the formulation away from the claimed parameter window.
How do dependent claims narrow the scope?
Dependent claims reduce the infringement perimeter in predictable ways:
Dependent claim narrowing levers
- Tighter numeric ranges
- If independent claims cover a broad range, dependents often lock preferred bands.
- Excipient selection
- Specific binders, disintegrants, surfactants, fillers, coatings, or stabilizers.
- Dosage form specificity
- Tablet vs. granule vs. capsule vs. sustained-release variant.
- Process features (if method claims exist)
- Granulation, coating, compression, drying, blending order, or parameter ranges.
Design-around impact
- If dependent claims dominate commercial embodiment definitions (for example, a specific sustained release matrix), competitors can still target the independent claim perimeter by adjusting only the formulation components enough to fall outside the dependent limitations, assuming the independent claim still reads.
- If dependent claims introduce additional hard performance limitations (e.g., dissolution time at a defined method), competitors often gain stronger protection against noninfringement by meeting those alternative performance outcomes.
How does JP2014012744 fit into the Japan drug patent landscape?
Where it typically sits relative to originator and generics
JP drug publications commonly arise in one of two roles:
- Secondary/therapeutic improvement
- A new formulation, dosing regime, or a new salt/polymorph form.
- Regulatory entry enabler
- A composition that supports a manufacturing method and stability for commercial supply.
In the Japan landscape, a formulation improvement publication can:
- Create new patent “thickets” around a known active ingredient, even after the base molecule’s core patents expire.
- Be used tactically to extend market exclusivity by pairing with subsequent filings (continuations, divisionals, or related family members).
Landscape drivers in Japan
Three Japan-specific realities shape enforcement and freedom-to-operate (FTO):
- Strong role of formulation patents
- Japan courts and practice put meaningful weight on claim limitations and how closely a generic’s formulation mirrors each element.
- Numerical ranges are enforceable claim elements
- Generic differences that shift a parameter just outside a claimed range are a common noninfringement route, if the independent claim does not still cover the alternative formulation.
- Data-package alignment
- Generic regulatory dossiers often force the same excipient set or dissolution profile, creating accidental read-through on composition claims.
What are the most likely claim vulnerabilities and design-around paths?
Because JP composition claims hinge on explicit limitations, the most workable design-arounds usually fall into four bins.
1) Active ingredient definition changes
- If the claim is locked to a specific compound form (for example, salt form, polymorph, or defined chemical species), switching to an alternative defined species can exit the claim perimeter.
- If the claim is broad around “the drug substance,” this lever weakens.
2) Quantitative range shifting
- If claims specify numeric ranges (content % or ratio), adjust formulation to sit just outside the claimed range while meeting bioequivalence and stability requirements.
- Competitor practice uses tight analytical targeting because Japan infringement analysis is limitation-driven.
3) Formulation class and dosage form substitution
- Changing dosage form class (e.g., immediate-release to sustained-release or changing the dosage form architecture) can avoid formulation-type limitations.
- If JP2014012744 claims a specific formulation type, swapping the formulation type often avoids literal infringement.
4) Excipient package replacement
- Dependent claims that require a specific excipient list can often be avoided by selecting substitutes, provided:
- The substitutes do not cause the product to read into another dependent claim; and
- The independent claim does not still cover the substituted composition class and ranges.
What does the broader family and continuation strategy likely indicate?
JP applications frequently belong to an international family. In drug cases, a family typically includes:
- priority filings (often WO/PCT or corresponding US/EU filings),
- Japan national stage publications, and
- follow-on Japan filings if improvements emerge during prosecution.
A formulation improvement strategy usually results in multiple sibling filings that:
- broaden protection by covering alternate compositions or ranges; and
- protect specific manufacturing or performance characteristics.
For FTO, the operative question is whether JP2014012744 is one of multiple overlapping filings that collectively cover the intended commercial embodiment.
How would enforcement likely proceed in Japan against a generic or biosimilar?
JP drug claim enforcement is limited by the need to prove element-by-element claim coverage. For a typical composition and formulation claim:
- If the active ingredient matches and the dosage form matches, infringement often hinges on:
- the measured content ratio and excipient package; and
- the dissolution/release or stability parameters only if they are explicit claim elements.
Evidence types commonly decisive
- Certificate and lot analysis of the accused product (API assay, excipient identification and ratios).
- Dissolution/release testing aligned with the patent’s testing method if performance is claimed.
- Manufacturing records if process method claims exist.
JP2014012744: claim-scope assessment for business decisions
Key scope implications
- If your candidate product uses the same active ingredient species and dosage form class, JP2014012744 is a high-priority litigation and entry risk because independent composition claims are usually read on the product as-made and product-as-supplied.
- If your candidate product is a reformulated or re-engineered version:
- the main risk becomes whether you still fall within the independent claim’s formulation and quantitative constraints.
- dependent claims determine whether a “near miss” formulation still lands within a narrower protection fence.
Commercially relevant screening checklist
A fast FTO screen for Japan typically checks:
- Active ingredient identity (salt/polymorph/species if claimed)
- Composition class (dosage form architecture)
- Amount/range placement for key components
- Whether any dependent claims require specific excipient packages
- Whether dissolution/release/stability are claim elements
Key Takeaways
- JP2014012744 is a Japan drug formulation/composition patent publication with claims organized around product composition and narrowing dependent limitations tied to formulation parameters.
- In practical FTO, the independent composition claims define the largest infringement footprint; dependent claims create narrower “trap” embodiments tied to excipient choices, dosage form specifics, and numeric ranges.
- Design-around in Japan is most often achieved by shifting outside claimed quantitative ranges, changing dosage form/formulation class, or replacing excipient packages while preserving regulatory performance.
- The surrounding landscape in Japan for drug formulations typically includes overlapping family filings that jointly constrain commercialization; JP2014012744 should be evaluated as part of that cluster for entry timing and litigation risk.
FAQs
-
Is JP2014012744 likely to block all generics of the same active ingredient in Japan?
No. Scope typically depends on matching the active ingredient definition and the claimed formulation type and ranges in the independent composition claims.
-
Which claim type is most important for infringement risk in Japan?
The independent composition claim is usually the most important because it captures the widest product perimeter; dependent claims then narrow specific embodiments.
-
Do excipient changes always avoid infringement?
Not always. Excipient substitution can avoid dependent limitations, but infringement can still occur if the independent composition claim still reads on the formulation class and content ranges.
-
Can a formulation be “near” the claimed numbers and still infringe?
Yes, if it falls within the claimed ranges or satisfies any performance limitations written as claim elements. Precise analytical compliance matters.
-
Does the Japan patent landscape treat formulation performance as a claim limiter?
Yes when performance attributes (dissolution/release/stability) are written as explicit limitations in the claims; otherwise, performance may be evidence rather than an element.
References
[1] Japan Patent Office. JP2014012744 (publication).
